Cargando…

HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E

Redifferentiation therapy with BRAF/MEK inhibitors to facilitate treatment with radioiodine represents a good choice for radioiodine-refractory differentiated thyroid carcinoma, but recent initial clinical outcomes were modest. MAPK rebound caused by BRAF/MEK inhibitors-induced activation of HER2/HE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Lingxiao, Jin, Yuchen, Liu, Min, Ruan, Maomei, Chen, Libo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386727/ https://www.ncbi.nlm.nih.gov/pubmed/28423638 http://dx.doi.org/10.18632/oncotarget.15773

Ejemplares similares

MAPK Inhibitors Enhance HDAC Inhibitor-Induced Redifferentiation in Papillary Thyroid Cancer Cells Harboring BRAF(V600E): An In Vitro Study
por: Fu, Hao, et al.
Publicado: (2019)

Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in BRAFV600 Melanoma: Current Status and Future Perspectives
por: Welti, Michèle, et al.
Publicado: (2022)

Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review
por: Andrews, Lily J, et al.
Publicado: (2021)

Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care
por: Louveau, Baptiste, et al.
Publicado: (2019)

OR09-4 Novel Murine Models of BrafV600E driven Papillary Thyroid Cancer
por: Casado Medrano, Victoria, et al.
Publicado: (2022)

Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib
por: Jafri, Sabih, et al.
Publicado: (2021)

The clinical significance of BRAFV600E mutations in pediatric papillary thyroid carcinomas
por: Li, Yangsen, et al.
Publicado: (2022)

MEK inhibitors in non-V600 BRAF mutations and fusions
por: Johnson, Douglas B., et al.
Publicado: (2020)

The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors
por: Coperchini, Francesca, et al.
Publicado: (2019)

Papillary thyroid cancer organoids harboring BRAF(V600E) mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies
por: Chen, Dong, et al.
Publicado: (2023)

The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study
por: Haist, Maximilian, et al.
Publicado: (2022)

Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines
por: Dorris, Emma R., et al.
Publicado: (2016)

Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long-term BRAF inhibition
por: Rowdo, Florencia Paula Madorsky, et al.
Publicado: (2020)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma
por: Satzger, Imke, et al.
Publicado: (2015)

Diagnostic Efficacy of BRAFV600E Immunocytochemistry in Thyroid Aspirates in Bethesda Category IV and Papillary Thyroid Carcinoma
por: Anand, Nidhi, et al.
Publicado: (2021)

BRAFV600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
por: Silver, Jennifer A., et al.
Publicado: (2021)

Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade
por: Penna, Ilaria, et al.
Publicado: (2015)

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
por: Saijo, Ken, et al.
Publicado: (2022)

BRAFV600E mutation positive metastatic melanoma in a young woman treated with anti-BRAF/anti MEK combination: a case report
por: Giovannoni, Sara, et al.
Publicado: (2015)

BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma
por: Mehnert, Janice M., et al.
Publicado: (2022)

Clinicopathological Characteristics of Papillary Thyroid Cancer in Children with Emphasis on Pubertal Status and Association with BRAFV600E Mutation
por: Poyrazoğlu, Şükran, et al.
Publicado: (2017)

Iodine nutritional status is not a direct factor in the prevalence of the BRAFV600E mutation in papillary thyroid cancer
por: Lin, Yan-Yu, et al.
Publicado: (2023)

X-linked inhibitor of apoptosis protein (XIAP) predicts disease-free survival in BRAFV600E mutant papillary thyroid carcinoma in middle eastern patients
por: Parvathareddy, Sandeep Kumar, et al.
Publicado: (2022)

Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy
por: Rostami, Elham, et al.
Publicado: (2017)

Relation Between F-18 FDG Uptake of PET/CT and BRAFV600E Mutation in Papillary Thyroid Cancer
por: Yoon, Seokho, et al.
Publicado: (2015)

Unfavorable efficacy to (131)I ablation in BRAFV600E mutant papillary thyroid carcinoma with positive TgAb
por: Zhang, Na, et al.
Publicado: (2017)

Identification of R-Spondin Gene Signature Predictive of Metastatic Progression in BRAFV(600E)-Positive Papillary Thyroid Cancer
por: da Silva, Sabrina Daniela, et al.
Publicado: (2022)

Radioactive Iodine Resistant Papillary Thyroid Cancer “Redifferentiated” With Dabrafenib
por: Zayouna, Christine, et al.
Publicado: (2021)

Durable Progression-Free Survival With the Use of BRAF and MEK Inhibitors in Four Cases With BRAF V600E-Mutated Gliomas
por: Fusco, Michael J., et al.
Publicado: (2021)

OR27-6 Combination Vemurafenib (BRAF Inhibitor)/Cobimetinib (MEK Inhibitor)/Atezolizumab (Anti-PDL1 Inhibitor) in BRAF-V600E Mutated Anaplastic Thyroid Cancer (ATC): Initial Safety and Feasibility
por: Cabanillas, Maria, et al.
Publicado: (2019)

Case report: Major pathologic response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with stage IIIA lung adenocarcinoma harboring BRAF V600E-mutation
por: Liu, Chaoyuan, et al.
Publicado: (2022)

Quantifying ERK activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling
por: Hamis, Sara J., et al.
Publicado: (2021)

Role of ultrasonographic features and quantified BRAFV600E mutation in lymph node metastasis in Chinese patients with papillary thyroid carcinoma
por: Guo, Liang, et al.
Publicado: (2019)

Detection of BRAFV600E in Liquid Biopsy from Patients with Papillary Thyroid Cancer Is Associated with Tumor Aggressiveness and Response to Therapy
por: Jensen, Kirk, et al.
Publicado: (2020)

Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases
por: Huang, Shuhui, et al.
Publicado: (2022)

Predicting BRAFV600E mutations in papillary thyroid carcinoma using six machine learning algorithms based on ultrasound elastography
por: Agyekum, Enock Adjei, et al.
Publicado: (2023)

Predicting (131)I-avidity of metastases from differentiated thyroid cancer using (18)F-FDG PET/CT in postoperative patients with elevated thyroglobulin
por: Liu, Min, et al.
Publicado: (2018)

Sinomenine Hydrochloride Promotes TSHR-Dependent Redifferentiation in Papillary Thyroid Cancer
por: Zhang, Jing, et al.
Publicado: (2022)

Sustained response of three pediatric BRAF(V600E) mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy
por: Toll, Stephanie A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_d7lb79d0anernmsagp1usr7rig